Physician profile
Joseph E Marks
NPI 1952897514
$5,285.22
in general payments reported to CMS, 2019-2025
33 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $1,052 · 2023: $1,060 · 2024: $1,247 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.21 | 2021-2025 | |
| Novo Nordisk INC | $729.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $599.16 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $477.54 | 2023-2025 | |
| Lilly USA, LLC | $467.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $327.62 | 2021-2025 | |
| Astellas Pharma US INC | $261.34 | 2021-2025 | Veozah |
| Amarin Pharma, INC. | $137.41 | 2021 | |
| Phathom Pharmaceuticals, INC. | $132.73 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $120.39 | 2021-2022 | |
| Glaxosmithkline, LLC. | $119.70 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $103.78 | 2022-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $89.25 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $80.53 | 2021 | |
| Merck Sharp & Dohme LLC | $75.95 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.78 | 2022 | |
| Amgen INC. | $54.56 | 2022-2025 | Evenity |
| Axsome Therapeutics, INC. | $53.66 | 2023-2025 | Symbravo, Auvelity |
| Exact Sciences Corporation | $50.30 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Horizon Therapeutics Plc | $49.32 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $45.20 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.62 | 2021-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $37.35 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $36.46 | 2021-2025 | Nexletol |
| Eisai INC. | $31.20 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $27.11 | 2021 | |
| Boston Scientific Corporation | $26.79 | 2024 | Watchman Access System |
| Mycovia Pharmaceuticals, INC. | $23.51 | 2023 | Vivjoa |
| Ibsa Pharma INC. | $20.40 | 2022 | |
| Corcept Therapeutics | $17.23 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.80 | 2023 | Xifaxan |
| Optinose US, INC. | $15.86 | 2021 | |
| Genentech USA, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.